STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.

By ChenOct 28, 2026

Score█████░░░░░5.0

VerdictCompetent work. Briefs at most.

Read at STAT

Summary from the source

Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.

Elaine Chen

The editor's rubric

Heuristic review

Leverage2 / 5: Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).; 15% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 20% of this desk’s rubric
Evidence2 / 5: Limited: single setting, weak baselines, or an observational association presented as causal.; 20% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 10% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 10% of this desk’s rubric
Stakes2 / 5: Benefits a professional community (practitioners, clinicians, engineers).; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	██░░░2/5	15%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	███░░3/5	20%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	██░░░2/5	20%	Limited: single setting, weak baselines, or an observational association presented as causal.
Novelty	██░░░2/5	10%	A new combination of known ideas.
Trajectory	██░░░2/5	10%	Some room to improve with obvious engineering.
Stakes	██░░░2/5	25%	Benefits a professional community (practitioners, clinicians, engineers).

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (outperforms); verification (error bars); stakes (major disease).

How the score was computed

rank-2026-10-18

Score█████░░░░░5.0

Score = 10 × (50% × adjusted merit / 10 + 25% × attention + 25% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 3.7 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 3.9 / 10; Shrunk toward the desk prior by editor confidence (30%).
Attention: 28%; Citations, upvotes, points, mentions.
Freshness: 95%; Half-life decay since publication.

No attention signals recorded yet.

The record

Reviewed by heuristic-v10 on Oct 28, 2026, 12:08 UTC. Paper type: news.
Categories: Biotech, Health, Pharma, chronic diseases, Clinical trials, diabetes, Eli Lilly, Novo Nordisk, Obesity
BRIEF, No.5 in the Front page edition of October 28, 2026.
TOP, No.4 in the News edition of October 28, 2026.